Researchers have identified two brain receptors that help the brain clear away amyloid beta, a hallmark of Alzheimer’s disease. By stimulating these receptors in mice, scientists increased levels of a natural amyloid-breaking enzyme, reduced buildup in the brain, and improved memory-related behavior. Because these receptors are common drug targets, the findings could open the door to affordable pill-based treatments with fewer side effects.
Read more HERE
Indiana University School of Medicine scientists have identified a promising drug target for Alzheimer’s disease. The team found that removing an enzyme from neurons in the brain substantially reduces amyloid plaques—a hallmark characteristic of the disease—and may provide further resilience against disease progression.
Read more HERE
In a world’s first, an NIH-funded randomized controlled trial of more than 2,800 older adults (the “ACTIVE Study”) has reported a modest amount of cognitive training significantly reduced Alzheimer Disease and related dementias diagnoses, as reported in Medicare data over a 20-year follow-up period. The results are published in Alzheimer’s & Dementia: Translational Research & Clinical Interventions,
Read the article about it HERE
Patients with dementia who participated in a Medicare-funded collaborative care program that provided support and medical advice for caregivers were able to remain in their home communities longer before entering nursing homes, according to a new study. This compares to those patients who were taking lecanemab, one of two approved drugs that have been shown to slow progression of Alzheimer’s in some patients, a February study published in Alzheimer’s & Dementia: Behavior & Socioeconomics of Aging found.
Scientists have found a potential new way to slow memory loss in Alzheimer’s, a neurodegenerative disorder that gradually damages memory and thinking, according to a new study.
Read it all HERE
Scientists at Tokyo Metropolitan University have turned to polymer physics to better understand one of the defining features of Alzheimer’s disease: the formation of tau protein fibrils. Their research shows that these fibrils do not form directly. Instead, tau proteins first gather into large clusters, similar to how polymers begin to crystallize. When researchers disrupted these early clusters, fibrils failed to develop in solution.
This finding points to a major shift in how future treatments for neurodegenerative diseases might be designed.
Read the article HERE